Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Cliff Diving: Evergreening & Other Oddities

Philip Seo, MD, MHS  |  Issue: September 2022  |  September 5, 2022

The glassblowers were in revolt.

The island of Murano, in the 13th century, was a perfect home for the glassblowing industry. Connected to Venice through a system of bridges, Murano was surrounded by waters that protected the city from the furnaces that fueled the glassblowers’ craft. The Republic of Venice dominated trade throughout the Mediterranean, which created a natural market for its wares.1 Life was good.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Too good.

As the renown of the Venetian glassblowers increased, other cities attempted to woo them away. The most common proffers included debt forgiveness and immunity from the prosecutorial system. Rome had a unique trump card: The papal home was able to offer forgiveness of sins to an adequately gifted artisan who agreed to relocate to the Eternal City.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Venetian glassblowers’ guild was aghast. The guild viewed glassblowing expertise as communal property, not belonging to any one artisan. The idea that any individual glassblower could pack his pipes and take that communal property to another city was anathema. The guild’s initial response was predictable: It simply forbade artisans from leaving Venice. Glassblowers who gave away guild secrets were subject to heavy fines and disallowed from returning to Venice to ply their craft.3 This worked about as well as you might have expected. Once artisans were outside city limits, the Venetian guild had limited ability to enforce its punishments on the artisans who now fell under the protection of Rome or an equally powerful city. So the guild came up with another incentive: cold hard cash.

Venice realized its riches depended on constant innovation, both in glassblowing and other areas. To entice artisans to bring new skill sets to Venice, the Venetians created the Statute on Industrial Brevets on March 19, 1474, which stated:4

Any person in this city who makes any new and ingenious contrivance, not made heretofore in our dominion, shall, as soon as it is perfected so that it can be used and exercised, give notice of the same to our office of Provveditori de Comun [State Judicial Office], it being forbidden up to 10 years for any other person in any territory and place of ours to make a contrivance in the form and resemblance thereof, without the consent and license of the author.

Thus, the modern patent was born.

Since then, the principles underlying the patent have remained surprisingly static: To encourage innovation, the government grants a time-limited monopoly to the innovator. During this period, the innovator alone reaps the rewards of their labors. When the monopoly expires, the information underlying the patent disseminates to spur further innovation.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:EthicsOpinionProfessional TopicsRheuminationsSpeak Out Rheum Tagged with:drug patentsevergreeninggene patentgeneric drugs

Related Articles

    U.S. Tribal Patent Deal Could Impact Generic Drug Market

    September 12, 2017

    (Reuters)—A groundbreaking deal between Allergan Plc. and a Native American tribe to shield the company’s patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts say, potentially dealing a blow to generic competition. Allergan said on Friday it had transferred patents on its blockbuster dry eye…

    U.S. Supreme Court Rejects Allergan Bid to Use Tribe to Shield Drug Patents

    April 16, 2019

    WASHINGTON (Reuters)—The U.S. Supreme Court has cast aside pharmaceutical company Allergan Plc.’s unorthodox bid to shield patents from a federal administrative court’s review by transferring them to a Native American tribe. The justices left in place a lower court ruling upholding the authority of a U.S. Patent and Trademark Office tribunal to decide the validity…

    Colchicine: An Ancient Drug with Modern Uses

    August 11, 2021

    Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550…

    The Unapproved-Drugs Initiative Is Coming to an End

    February 16, 2021

    On Friday, Nov. 20, 2020, the U.S. Department of Health and Human Services (HHS) published a Notice through the Federal Register announcing the withdrawal of guidance documents that established the Unapproved Drugs Initiative. This Notice brings to an end a 14-year-old program that has been blamed for significantly contributing to the rising cost of some…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences